PL4005570T3 - Pridopidyna do zastosowania w leczeniu zespołu retta - Google Patents

Pridopidyna do zastosowania w leczeniu zespołu retta

Info

Publication number
PL4005570T3
PL4005570T3 PL22150695.9T PL22150695T PL4005570T3 PL 4005570 T3 PL4005570 T3 PL 4005570T3 PL 22150695 T PL22150695 T PL 22150695T PL 4005570 T3 PL4005570 T3 PL 4005570T3
Authority
PL
Poland
Prior art keywords
pridopidine
treatment
retts syndrome
retts
syndrome
Prior art date
Application number
PL22150695.9T
Other languages
English (en)
Polish (pl)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL4005570T3 publication Critical patent/PL4005570T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL22150695.9T 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta PL4005570T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16

Publications (1)

Publication Number Publication Date
PL4005570T3 true PL4005570T3 (pl) 2024-09-23

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta

Country Status (13)

Country Link
EP (2) EP3512506B1 (https=)
JP (1) JP6977029B2 (https=)
CN (1) CN109982686A (https=)
AU (1) AU2017326013B2 (https=)
BR (1) BR112019005040A2 (https=)
CA (1) CA3036984C (https=)
DK (2) DK3512506T3 (https=)
ES (2) ES2909557T3 (https=)
HU (1) HUE058314T2 (https=)
IL (1) IL265342B2 (https=)
MX (1) MX388845B (https=)
PL (2) PL4005570T3 (https=)
WO (1) WO2018053280A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20161220A1 (es) * 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
PL3512506T3 (pl) 2022-05-30
IL265342A (en) 2019-05-30
JP2019532926A (ja) 2019-11-14
EP4005570B1 (en) 2024-05-15
MX388845B (es) 2025-03-20
HUE058314T2 (hu) 2022-07-28
JP6977029B2 (ja) 2021-12-08
AU2017326013A1 (en) 2019-04-11
EP3512506A4 (en) 2020-05-27
CN109982686A (zh) 2019-07-05
ES2909557T3 (es) 2022-05-09
DK4005570T3 (da) 2024-08-19
BR112019005040A2 (pt) 2019-07-16
AU2017326013B2 (en) 2020-12-24
EP3512506B1 (en) 2022-01-26
CA3036984C (en) 2023-07-18
WO2018053280A1 (en) 2018-03-22
DK3512506T3 (da) 2022-04-19
ES2986807T3 (es) 2024-11-12
IL265342B2 (en) 2023-06-01
EP4005570A1 (en) 2022-06-01
EP3512506A1 (en) 2019-07-24
CA3036984A1 (en) 2018-03-22
MX2019003069A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL256056A (en) Ezh2 inhibitors for treating lymphoma
IL290993A (en) Methods of diagnosing and treating tourette syndrome
PL4005570T3 (pl) Pridopidyna do zastosowania w leczeniu zespołu retta
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
IL252602B (en) Oral care compositions and methods of use
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
PL3179991T3 (pl) Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
HRP20181661T1 (hr) Inhibitori jak1 za liječenje mijelodisplastičnih sindroma
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
HUE037250T2 (hu) Duokarmicin ADC-k (antitest-hatóanyag konjugátumok) húgyhólyagrák kezelésében történõ alkalmazásra
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
IL251759B (en) Compositions and methods for treating insomnia
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3302207A4 (en) Surface treatment apparatuses and methods
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
IL251904A0 (en) Apilimod for use in the treatment of melanoma
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra